产肠毒素性大肠杆菌 (ETEC)是引起幼畜、婴幼儿及旅游者腹泻的重要病原菌之一。肠毒素是其主要的毒力因子 ,包括耐热性肠毒素 (ST)和热敏感肠毒素 (L T)。STI基因和 L TB基因融合后产生的融合蛋白不仅增强了 STI 的免疫原性 ,而且降低了...产肠毒素性大肠杆菌 (ETEC)是引起幼畜、婴幼儿及旅游者腹泻的重要病原菌之一。肠毒素是其主要的毒力因子 ,包括耐热性肠毒素 (ST)和热敏感肠毒素 (L T)。STI基因和 L TB基因融合后产生的融合蛋白不仅增强了 STI 的免疫原性 ,而且降低了 STI 的生物毒性 ,这就给抗幼畜腹泻的基因工程亚单位苗开发带来了新的希望。展开更多
Management of acute diarrhea remains a global challenge, particularly in resource-limiting countries. Oral rehydration solution (ORS), a passive rehydrating therapy developed approximately 40 years ago, remains the ma...Management of acute diarrhea remains a global challenge, particularly in resource-limiting countries. Oral rehydration solution (ORS), a passive rehydrating therapy developed approximately 40 years ago, remains the mainstay treatment. Although ORS is effective for hydration, since it does not inhibit enterotoxin-mediated excessive secretion, reduced absorption and compromised barrier function - the primary mechanisms of diarrhea, ORS does not offer a rapid relief of diarrhea symptom. There are a few alternative therapies available, yet the use of these drugs is limited by their expense, lack of availability and/or safety concerns. Novel anti-diarrheal therapeutic approaches, particularly those simple affordable therapies, are needed. This article explores intestinal calcium-sensing receptor (CaSR), a newly uncovered target for therapy of diarrhea. Unlike others, targeting this host antidiarrheal receptor system appears “all-inclusive”: it is anti-secretory, pro-absorptive, anti-motility, and anti-inflammatory. Thus, activating CaSR reverses changes of both secretory and inflammatory diarrheas. Considering its unique property of using simple nutrients such as calcium, polyamines, and certain amino acids/oligopeptides as activators, it is possible that through targeting of CaSR with a combination of specific nutrients, novel oral rehydrating solutions that are inexpensive and practical to use in all countries may be developed.展开更多
文摘产肠毒素性大肠杆菌 (ETEC)是引起幼畜、婴幼儿及旅游者腹泻的重要病原菌之一。肠毒素是其主要的毒力因子 ,包括耐热性肠毒素 (ST)和热敏感肠毒素 (L T)。STI基因和 L TB基因融合后产生的融合蛋白不仅增强了 STI 的免疫原性 ,而且降低了 STI 的生物毒性 ,这就给抗幼畜腹泻的基因工程亚单位苗开发带来了新的希望。
基金Supported by The National Institute of Health NICHD,award No.K08HD079674the CDNHF/NASPGHAN foundation,award No.00102979the Children’s Miracle Network
文摘Management of acute diarrhea remains a global challenge, particularly in resource-limiting countries. Oral rehydration solution (ORS), a passive rehydrating therapy developed approximately 40 years ago, remains the mainstay treatment. Although ORS is effective for hydration, since it does not inhibit enterotoxin-mediated excessive secretion, reduced absorption and compromised barrier function - the primary mechanisms of diarrhea, ORS does not offer a rapid relief of diarrhea symptom. There are a few alternative therapies available, yet the use of these drugs is limited by their expense, lack of availability and/or safety concerns. Novel anti-diarrheal therapeutic approaches, particularly those simple affordable therapies, are needed. This article explores intestinal calcium-sensing receptor (CaSR), a newly uncovered target for therapy of diarrhea. Unlike others, targeting this host antidiarrheal receptor system appears “all-inclusive”: it is anti-secretory, pro-absorptive, anti-motility, and anti-inflammatory. Thus, activating CaSR reverses changes of both secretory and inflammatory diarrheas. Considering its unique property of using simple nutrients such as calcium, polyamines, and certain amino acids/oligopeptides as activators, it is possible that through targeting of CaSR with a combination of specific nutrients, novel oral rehydrating solutions that are inexpensive and practical to use in all countries may be developed.
